Regenicin, Inc. (RGIN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Regenicin, Inc. (RGIN) trades at $0.0001. Regenicin, Inc. is a biotechnology company focused on developing and commercializing tissue-engineered skin substitutes. Their lead products, NovaDerm and TempaDerm, aim to address burns, chronic wounds, and plastic surgery needs. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for RGIN: RGIN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RGIN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on RGIN.
How is this calculated? →Regenicin, Inc. (RGIN) Healthcare & Pipeline Overview
Regenicin, Inc. is a biotechnology company specializing in tissue-engineered skin substitutes, including NovaDerm and TempaDerm, targeting the treatment of burns and chronic wounds. Operating within the competitive healthcare sector, Regenicin seeks to restore healthy human skin qualities through innovative regenerative medicine technologies.
What Is the Investment Thesis for RGIN?
Regenicin, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on tissue-engineered skin substitutes addresses a significant market need in wound care and burn treatment. Key value drivers include the successful commercialization of NovaDerm and TempaDerm, which could generate substantial revenue if adopted by hospitals and clinics. Growth catalysts include positive clinical trial results demonstrating the efficacy and safety of their products, as well as strategic partnerships with larger healthcare companies for distribution and marketing. However, potential risks include the company's limited financial resources, the regulatory approval process for medical devices, and competition from established players in the wound care market. The company's small market capitalization and OTC listing add further complexity to the investment profile. Investors should carefully consider these factors before investing in RGIN.
Based on FMP financials and quantitative analysis
RGIN Key Highlights
Regenicin, Inc. specializes in tissue-engineered skin substitutes, addressing a critical need in wound care and burn treatment.
- The company's product portfolio includes NovaDerm for burns and TempaDerm for smaller wounds like ulcers.
- Regenicin aims to restore the qualities of healthy human skin through advanced regenerative medicine technologies.
- The company operates in the competitive biotechnology sector, requiring significant capital for research and development.
- RGIN's small market capitalization and OTC listing present both opportunities and risks for investors.
Who Are RGIN's Competitors?
RGIN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGIN's Key Strengths?
Proprietary tissue-engineering technology.
- Focus on a specific niche market (wound care).
- Potential for high margins on specialized products.
- Innovative products addressing unmet medical needs.
What Are RGIN's Weaknesses?
Limited financial resources.
- Small number of employees.
- Dependence on a limited product portfolio.
- OTC listing may limit investor access.
What Could Drive RGIN Stock Higher?
Positive results from ongoing clinical trials of NovaDerm and TempaDerm could drive investor interest.
- Potential partnerships with larger healthcare companies for distribution and marketing.
- Regulatory approvals for new indications or geographic markets.
- Increasing awareness of the benefits of tissue-engineered skin substitutes.
- Growing demand for advanced wound care solutions.
What Are the Key Risks for RGIN?
Financial-distress signal — its Altman Z-Score of -2.86 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Limited financial resources may hinder the company's ability to fund research and development.
- Regulatory hurdles and approval delays could delay the commercialization of their products.
- Competition from established wound care companies with greater resources.
- The company's small size and OTC listing may limit investor access and liquidity.
- Dependence on a limited product portfolio increases vulnerability to market changes.
What Are the Growth Opportunities for RGIN?
- Expansion into New Therapeutic Areas: Regenicin could expand its product portfolio to address other skin-related conditions, such as diabetic ulcers, surgical wounds, and cosmetic applications. The market for advanced wound care products is estimated to reach $22 billion by 2028, providing a significant opportunity for Regenicin to diversify its revenue streams. Successful expansion would require additional research and development, as well as regulatory approvals for new indications. This strategy could enhance Regenicin's market position and reduce its reliance on a limited number of products.
- Strategic Partnerships and Collaborations: Partnering with larger pharmaceutical or medical device companies could provide Regenicin with access to broader distribution networks, marketing expertise, and financial resources. Collaborations could also facilitate clinical trials and regulatory approvals. The pharmaceutical industry is increasingly seeking innovative technologies to enhance their product offerings, making strategic partnerships a viable growth strategy for Regenicin. Successful partnerships could accelerate the commercialization of NovaDerm and TempaDerm and increase their market penetration.
- Geographic Expansion: Regenicin could expand its market reach beyond the United States to international markets, such as Europe and Asia, where there is a growing demand for advanced wound care solutions. The global wound care market is expected to grow at a CAGR of 6% over the next five years, driven by the aging population and the increasing prevalence of chronic diseases. Expanding into new geographic markets would require regulatory approvals in each country, as well as establishing distribution channels and marketing strategies tailored to local market conditions.
- Development of Next-Generation Skin Substitutes: Investing in research and development to create next-generation skin substitutes with enhanced properties, such as improved healing rates, reduced scarring, and enhanced cosmetic outcomes, could provide Regenicin with a competitive advantage. The market for advanced skin substitutes is constantly evolving, with new technologies and materials emerging. Staying at the forefront of innovation is crucial for Regenicin to maintain its market position and attract new customers. This strategy would require significant investment in research and development, as well as a strong focus on intellectual property protection.
- Focus on Personalized Medicine: Tailoring skin substitutes to individual patient characteristics, such as genetic profile and wound type, could improve treatment outcomes and reduce the risk of complications. Personalized medicine is a growing trend in healthcare, with increasing emphasis on individualized treatment approaches. Regenicin could leverage its expertise in tissue engineering to develop personalized skin substitutes that are optimized for each patient's specific needs. This strategy would require advanced diagnostic capabilities and manufacturing processes, as well as a strong focus on data analytics and bioinformatics.
What Are RGIN's Competitive Advantages?
- Proprietary tissue-engineering technology.
- Patented NovaDerm and TempaDerm products.
- Specialized expertise in regenerative medicine.
- Potential for strong brand recognition in the wound care market.
What Does RGIN Do?
Regenicin, Inc., originally incorporated as Windstar, Inc. in 2007, rebranded in July 2010 to focus on regenerative medicine. Headquartered in Little Falls, New Jersey, the company is dedicated to developing and commercializing tissue-engineered skin substitutes. Their primary focus is on restoring the qualities of healthy human skin through innovative technologies. Regenicin's product portfolio includes NovaDerm, a multi-layered, tissue-engineered living skin substitute designed for the treatment of burns. NovaDerm aims to provide a superior alternative to traditional skin grafting by offering a living, functional skin replacement. The company also offers TempaDerm, a similar product intended for treating smaller wound areas, such as ulcers. TempaDerm is designed to accelerate healing and reduce scarring in chronic wounds. Regenicin's products target a range of applications, including the treatment of burns, chronic wounds, and various plastic surgery procedures. The company aims to address the significant unmet need for advanced wound care solutions that promote effective and lasting skin regeneration. Regenicin's small size and focus on specialized products position it as a niche player within the broader biotechnology and wound care market.
What Products and Services Does RGIN Offer?
- Develops tissue-engineered skin substitutes.
- Focuses on products for treating burns.
- Offers solutions for chronic wound care.
- Provides products for plastic surgery procedures.
- Aims to restore healthy human skin qualities.
- Commercializes innovative regenerative medicine technologies.
How Does RGIN Make Money?
- Develops and patents tissue-engineered skin substitutes.
- Manufactures NovaDerm and TempaDerm products.
- Seeks regulatory approvals for their products.
- Commercializes products through direct sales or partnerships.
What Industry Does RGIN Operate In?
Regenicin, Inc. operates within the biotechnology industry, specifically focusing on regenerative medicine and wound care. The market for tissue-engineered skin substitutes is driven by the increasing prevalence of chronic wounds, burns, and the demand for advanced wound care solutions. The competitive landscape includes established players offering traditional wound care products, as well as other biotechnology companies developing innovative regenerative therapies. Regenicin's success depends on its ability to differentiate its products through superior efficacy, safety, and cost-effectiveness. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Who Are RGIN's Key Customers?
- Hospitals and burn centers.
- Wound care clinics.
- Plastic surgeons.
- Patients with burns and chronic wounds.
Company Profile
Regenicin, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Little Falls, US. The company is led by CEO Randall E. McCoy. RGIN has traded publicly since 2009.
Key Financial Metrics
Return on equity for Regenicin, Inc. stands at 11.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Regenicin, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.86 places it in the distress zone, a signal of elevated financial risk.
RGIN Financials
Bull Case vs Bear Case
Bull Case
- Proprietary tissue-engineering technology.
- Focus on a specific niche market (wound care).
- Potential for high margins on specialized products.
- Innovative products addressing unmet medical needs.
Bear Case
- Limited financial resources.
- Small number of employees.
- Dependence on a limited product portfolio.
- OTC listing may limit investor access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RGIN Latest News
No recent news available for RGIN.
RGIN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGIN.
Price Targets
Wall Street price target analysis for RGIN.
RGIN MoonshotScore
What does this score mean?
The MoonshotScore rates RGIN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Randall E. McCoy
CEO
Randall E. McCoy serves as the CEO of Regenicin, Inc. His background includes experience in managing small teams and overseeing the development and commercialization of biotechnology products. He is responsible for the strategic direction and overall management of the company. His leadership is focused on advancing Regenicin's tissue-engineered skin substitute technologies and expanding their market reach. He manages a small team of 3 employees.
Track Record: Under Randall E. McCoy's leadership, Regenicin, Inc. has focused on developing and commercializing NovaDerm and TempaDerm. Key milestones include securing patents for their technology and conducting clinical trials to demonstrate the efficacy of their products. He has navigated the challenges of operating a small biotechnology company with limited resources.
RGIN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Regenicin, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited information available to investors, and trading activity may be less transparent compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited liquidity, price volatility, and lack of regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements.
- Assess the company's management team and their experience.
- Research the company's products and technology.
- Evaluate the company's competitive landscape.
- Understand the regulatory environment in which the company operates.
- Check for any legal or regulatory issues.
- Consult with a financial advisor.
- Patents for their tissue-engineering technology.
- Focus on developing innovative wound care solutions.
- Clinical trials demonstrating the efficacy of their products.
- Company has been in operation since 2007.
- Headquartered in Little Falls, New Jersey.
Common Questions About RGIN (Healthcare)
What does Regenicin, Inc. do?
Regenicin, Inc. is a biotechnology company specializing in the development and commercialization of tissue-engineered skin substitutes. Their primary products, NovaDerm and TempaDerm, are designed to treat burns and chronic wounds by restoring the qualities of healthy human skin. The company operates within the regenerative medicine sector, aiming to provide innovative solutions for wound care and plastic surgery procedures.
What do analysts say about RGIN stock?
As of 2026-03-18, there is no readily available analyst coverage for Regenicin, Inc. (RGIN) due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the company's financial condition, product pipeline, and competitive landscape before making any investment decisions.
What are the main risks for RGIN?
Regenicin, Inc. faces several key risks, including limited financial resources, regulatory hurdles, and competition from established wound care companies. The company's reliance on a small number of products increases its vulnerability to market changes and potential product failures. As an OTC-listed company, RGIN is subject to less stringent regulatory requirements, which may increase the risk of fraud or mismanagement. Investors should carefully consider these risks before investing in RGIN.
What are the key factors to evaluate for RGIN?
Evaluate RGIN on fundamentals, analyst consensus, and risk factors. Regenicin, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does RGIN data refresh on this page?
RGIN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RGIN's recent stock price performance?
Regenicin, Inc. (RGIN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary tissue-engineering technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGIN overvalued or undervalued right now?
Regenicin, Inc. (RGIN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RGIN before investing?
Before investing in Regenicin, Inc. (RGIN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or less reliable than exchange-listed data.